2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1986

Insights into Osteoarthritis Progression by Gene Expression and miRNA Profiling of Mesenchymal Stromal Cells from Medial and Lateral Femoral Condyles
Abstract Number: 1947

Integrating Genetic Risk Scores and Pre-Diagnostic Metabolomics to Infer Dysregulated Mechanisms in Rheumatoid Arthritis in Women
Abstract Number: 2741

Integration of Single Cells from Inflammatory Disease Tissues Reveals Common and Unique Pathogenic Cell States
Abstract Number: 233

Intensive CBT Is Effective in the Treatment of Significant Functional Impairment and Psychological Distress Found in Fibromyalgia: But Can We Improve Depressive Symptoms?
Abstract Number: 1941

Interactions Between Genome-Wide Genetic Factors and Current Smoking in Determining SLE Risk
Abstract Number: 2031

Interferon Alpha Promotes Caspase-Dependent Apoptosis Independently of Reactive Oxygen Species in Ultraviolet B-Exposed Keratinocytes
Abstract Number: 5

Interferon Kappa Promotes the Development of Psoriasis
Abstract Number: 1026

Interferon Lambda Promotes Age-Associated B Cells
Abstract Number: 93

Interferon Pathway Activation in T Follicular Helper (Tfh) Cell Subsets in Human Myositis
Abstract Number: 777

Interferon Response Gene Expression Differs in Whole Blood, Peripheral Blood Mononuclear Cells, Monocytes, Dendritic Cells, Neutrophils, and Skin Tissue in Patients with the Autoinflammatory Interferonopathies, CANDLE and SAVI
Abstract Number: 814

Interferon Signature and Cytokine Patterns Define Novel Autoinflammatory Diseases
Abstract Number: 2900

Interferon Signature Predicts Response to Tofacitinib in Haploinsufficiency of A20
Abstract Number: 884

Interferon-Alpha Disrupts Multiple B Cell Tolerance Mechanisms in 3H9 Mice
Abstract Number: L06

Interferon-gamma (IFN-γ) Neutralization with Emapalumab and Time to Response in Patients with Macrophage Activation Syndrome (MAS) Complicating Systemic Juvenile Idiopathic Arthritis (s-JIA) who failed High-Dose Glucocorticoids
Abstract Number: 1765

Interferon-gamma Supports Transcriptional Activity of BIRC5 in CD4+ T Cells in Established Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].